Vectura gets planning approval to build £58m R&D facility in Bristol, UK

WCN Editorial Team 29 Sep 2022 EUROPE BUILDINGS

Biotech firm Vectura has secured planning approval from the South Gloucestershire Council for the construction of a £58m research and development (R&D) facility in Bristol, UK.

Vectura specialises in asthma inhalers.

The planned 10,000m² Inhalation Centre of Excellence will be constructed at Bristol & Bath Science Park in south-west England.

The Chippenham-based asthma inhaler producer is understood to have lined up Willmott Dixon for the construction of the facility, reported Construction Enquirer.

Construction of the facility is anticipated to complete in 2025.

Vectura CEO Michael Austwick said: “The new-build will enable our already successful pharmaceutical company to continue and expand upon its vital work, providing innovative inhalation and other advanced drug delivery solutions that have the potential to improve the lives of patients around the world.

“For nearly 25 years, Vectura has been providing a combination of formulation science, device technology and pharmaceutical development expertise, helping our partners and licensees develop products which are used by 10 million patients worldwide. This new facility will help us to build on this successful track record, increasing workspace capacity and attracting talent to the area.”

The facility aims to achieve ‘Excellent’ rating with BREEAM.

In September 2021, Vectura was acquired in a £1bn deal by tobacco major Philip Morris.

----------------------------------------------------------------------------------------------------------------

Credit: Illustration of Inhalation Centre of Excellence. Credit: Vectura.

With 11 websites and newsletters covering all the key areas within the construction industry, World Construction Industry Network is the leading global construction information resource. READ ABOUT US
PRIVACY POLICY

STAY IN TOUCH!

LATEST TWEETS

World Construction Network | www.worldconstructionnetwork.com is a product of GlobalData. Copyright © 2022 GlobalData. All rights reserved.